Yondelis (Trabectedin) Patent Expiration, LOE Window & CMS Spending

Yondelis (Trabectedin) by Johnson & Johnson: FDA Orange Book LOE 2028-07-07, 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN207953 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-07-07
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$355K
2024 Medicaid Spend$3.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 22.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.